Home › NDC Lookup › Ingredients › Glipizide › 50090-0503-00
Glipizide 10 mg Tablet, 30-count — NDC 50090-0503-00 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Glipizide 10 mg Tablet, 30-count — NDC 50090-0503-0 (Billing 50090-0503-00)

by A-S Medication Solutions · 30 TABLET in 1 BOTTLE

This is a package of 30 tablets of Glipizide 10 mg Tablet from A-S Medication Solutions, marketed since Feb 1995 and currently FDA-listed. It is the main listing for this product, which comes in 6 package sizes.

NDC 50090-0503-00
🏷️ FDA NDC (as labeled) 50090-0503-0 billing pads the package segment with a zero
This package
Contains30-count Pack sizes6 compare ↓
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 2, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 50090-0503-0
Product NDC 50090-0503
11-digit billing NDC 50090050300
NCPDP billing unit EA — each (per item)
Application # ANDA074223
SPL Set ID 04e18105-0bd2-4353-b7d2-a73749de32b8
Established class (EPC) Sulfonylurea
Chemical class Sulfonylurea Compounds
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1995-02-27
Route ORAL
Dosage form TABLET
Substance GLIPIZIDE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 001776
GCN 10841
HICL code 000803
Ingredient (HICL) Glipizide
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C4
Therapeutic class — intermediate (HIC2) Antihyperglycemics
HIC3 code C4K
Therapeutic class — specific (HIC3) Antihyperglycemic, Insulin-Release Stimulant Type
AHFS code 68:20.20.00
AHFS class Sulfonylureas
FDB label name GLIPIZIDE 10 MG TABLET
FDB brand name Glipizide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 001776
  • GCN: 10841
  • HICL (First Databank): 000803
  • AHFS class code: 68:20.20.00
Why two NDCs? The FDA registers this code as 50090-0503-0 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 50090-0503-00. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name GLIPIZIDE 10 MG TABLET Ingredient Glipizide
📖 What it is MedlinePlus · NLM

Glipizide is used along with diet and exercise, and sometimes with other medications, to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). Glipizide is in a class of medications called sulfonylureas. Glipizide lowers blood sugar by causing the pancreas to produce insulin (a natural substance that is needed to break down sugar in the body) and helping the body use insulin efficiently. This medication will only help lower blood sugar in people whose bodies produce insulin naturally. Glipizide is not...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Glipizide helps lower your blood sugar by prompting your pancreas to release more insulin — especially after meals. It's used in type 2 diabetes alongside diet and exercise, not as...
  • What exactly is glipizide supposed to do for my diabetes?
  • The regular tablet works relatively quickly and is usually taken about 30 minutes before a meal. The extended-release tablet (including the brand Glucotrol XL) releases the medicin...
  • What's the difference between the regular tablet and the extended-release tablet?
📖 Read our full Glipizide guide →
1
Nutrient depletion considerations

Glipizide may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
50090-0503-00 You're viewing this Main listing 30 TABLET in 1 BOTTLE 2014-11-28 — Active
50090-0503-01 50090-0503-1 60 TABLET in 1 BOTTLE 2014-11-28 — Active
50090-0503-02 50090-0503-2 100 TABLET in 1 BOTTLE 2016-06-29 — Active
50090-0503-04 50090-0503-4 200 TABLET in 1 BOTTLE 2016-06-29 — Discontinued by firm
50090-0503-05 50090-0503-5 90 TABLET in 1 BOTTLE 2016-06-29 — Active
50090-0503-06 50090-0503-6 180 TABLET in 1 BOTTLE 2016-06-29 — Active

You're viewing the smallest of 6 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This is a 30-count package — 30 tablet in 1 bottle.
How does this package differ from NDC 50090-0503-01?
Both are Glipizide 10 mg Tablet — the drug itself is identical. This page's package is the 30-count one, while NDC 50090-0503-01 is the 60 tablets package.
What NDC number is used to bill for this package of Glipizide 10 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Glipizide 10 mg 50268-0362-15 AvPAK 50 tablets $0.045 AB Availability likely —
Glipizide 10 mg 69584-0310-10 Oxford 100 tablets $0.045 AB Availability likely —
Glipizide 10 mg 60687-0701-01 American 100 tablets $0.045 AB Availability likely —
Glipizide 10 mg 00591-0461-01 Actavis 100 tablets $0.045 AB Availability likely —
Glipizide 10 mg 68645-0575-59 Legacy 60 tablets $0.045 AB Availability likely —
Glipizide 10 mg 72888-0117-00 Advagen 1000 tablets $0.045 AB Availability likely —
Glipizide 10 mg 60505-0142-00 Apotex 100 tablets $0.045 AB Availability likely —
Glipizide 10 mg 62559-0316-10 ANI 1000 tablets $0.045 AB Availability likely —
Glipizide 10 mg 63187-0993-30 Proficient 30 tablets — AB FDA listed —
Glipizide 10 mg 71610-0105-53 Aphena 60 tablets — AB FDA listed —
Glipizide 10 mg 00615-8408-39 NCS 30 tablets — AB FDA listed —
Glipizide 10 mg 50090-6996-00 A-S 90 tablets — AB FDA listed —
Glipizide 10 mg 71610-0668-53 Aphena 60 tablets — AB FDA listed —
Glipizide 10 mg 80425-0437-01 Advanced 30 tablets — AB FDA listed —
Glipizide 10 mg 51655-0106-25 Northwind 60 tablets — AB FDA listed —
Glipizide 10 mg 68071-4232-01 NuCare 100 tablets — AB FDA listed —
Glipizide 10 mg 68788-0142-01 Preferred 100 tablets — AB FDA listed —
Glipizide 10 mg 68788-4017-01 Preferred 100 tablets — AB FDA listed —
Glipizide 10 mg 70518-0579-00 REMEDYREPACK 180 tablets — AB FDA listed —
Glipizide 10 mg 71335-0618-01 Bryant 60 tablets — AB FDA listed —
Glipizide 10 mg 71335-9614-01 Bryant 60 tablets — AB FDA listed —
Glipizide 10 mg 72162-2102-00 Bryant 1000 tablets — AB FDA listed —
Glipizide 10 mg 80425-0549-01 Advanced 30 tablets — AB FDA listed —
Glipizide 10 mg 43063-0861-14 PD-Rx 14 tablets — AB FDA listed —
Glipizide 10 mg 50090-7197-00 A-S 90 tablets — AB FDA listed —
Glipizide 10 mg 72789-0510-30 PD-Rx 30 tablets — AB FDA listed —
Glipizide 10 mg 82804-0960-00 Proficient 100 tablets — AB FDA listed —
Glipizide 10 mg 68071-4124-02 NuCare 120 tablets — AB FDA listed —
Glipizide 10 mg 50090-7405-00 A-S 90 tablets — AB FDA listed —
Glipizide 10 mg 67046-0367-03 Coupler 30 tablets — AB FDA listed —
Glipizide 10 mg 50090-7735-00 A-S 90 tablets — AB FDA listed —
Glipizide 10 mg 51407-0621-10 Golden 1000 tablets — AB FDA listed —
Glipizide 10 mg 72789-0463-86 PD-Rx 360 tablets — AB FDA listed —
Glipizide 10 mg 63187-0811-30 Proficient 30 tablets — AB FDA listed —
Glipizide 10 mg 66267-0099-30 NuCare 30 tablets — AB FDA listed —
Glipizide 10 mg 72162-2215-00 Bryant 1000 tablets — AB FDA listed —
Glipizide 10 mg 68071-3974-08 NuCare 180 tablets — AB FDA listed —
Glipizide 10 mg 71335-2540-01 Bryant 60 tablets — AB FDA listed —
Glipizide 10 mg 68071-4643-01 NuCare 100 tablets — AB FDA listed —
Glipizide 10 mg 50090-0505-00 A-S 30 tablets — AB FDA listed —
Glipizide 10 mg 50090-7404-00 A-S 30 tablets — AB FDA listed —
Glipizide 10 mg 50090-7734-00 A-S 30 tablets — AB FDA listed —
Glipizide 10 mg 68788-4061-01 Preferred 100 tablets — AB FDA listed —
Glipizide 10 mg 68788-8138-01 Preferred 100 tablets — AB FDA listed —
Glipizide 10 mg 51655-0810-25 Northwind 60 tablets — AB FDA listed —
Glipizide 10 mgthis 50090-0503-00 A-S 30 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1995
On the market since
Feb 1995
📍
2026
Currently FDA-listed
31 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeRound
ImprintWatson;461
Size1 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3SY5LH9PMK
    Anhydrous lactose is a milk sugar with no water content. It acts as a filler and binder in tablets and capsules, adding bulk and helping ingredients stick together.
  • UNII M28OL1HH48
    Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
  • UNII 4ELV7Z65AP
    Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerA-S Medication Solutions
Application holderWATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
FDA applicationANDA074223 (ANDA)
Labeler code50090
First marketedFeb 1995
Product typeHuman Prescription Drug
Portfolio2,811 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Glipizide — the program that covers self-administered drugs. 8 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Glipizide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$13.01M
Claims incl. refills
1.1M
Beneficiaries
795.9K
Spend / beneficiary
$16.34
Spend / claim
$12.36
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by A-S Medication Solutions. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 5 other package presentations of this same product, including 60 tablets (50090-0503-01), 90 tablets (50090-0503-05), 100 tablets (50090-0503-02). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
A-S Medication Solutions is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.